125 results on '"Afzali, Anita"'
Search Results
2. Indications and safety of newer IBD treatments in the older patient
3. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
4. Clinical Long-Term Outcomes of Patient-Reported Outcomes in the Prospective Real-World Tofacitinib Response in Ulcerative Colitis Registry
5. Surgery for Crohn’s Disease Is Associated With a Dysbiotic Microbiome and Metabolome: Results From Two Prospective Cohorts
6. Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies
7. Pregnant women with immune mediated inflammatory diseases who discontinue biologics have higher rates of disease flare
8. EFFICACY AND SAFETY OF GUSELKUMAB THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS OF THE GALAXI 2 G 3 PHASE 3 STUDIES
9. Surgery for Crohn’s Disease Is Associated with a Dysbiotic Microbiome and Metabolome: Results from Two Prospective Cohorts
10. Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program
11. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
12. Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study
13. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
14. Clinical long-term outcomes of patient-reported outcomes in the prospective real-world Tofacitinib Response in Ulcerative Colitis (TOUR) registry
15. S26 Clinical Practice Experience With Subcutaneous Vedolizumab for the Treatment of Patients With Ulcerative Colitis and Crohn’s Disease
16. Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension.
17. S847 Efficacy of Guselkumab in Patients With Moderately to Severely Active Crohn’s Disease Not in Clinical Response at Week 12: Results From the GALAXI 1 Study
18. S851 Efficacy and Safety of Guselkumab for Crohn’s Disease Through 3 Years: GALAXI-1 Long-Term Extension
19. S1027 Impact of Prior Biologic Exposure on the Durability of 3-Year Continuous Ozanimod Treatment
20. S1774 Women in GI: Empowered Women Empower Women—Impact of the Second Annual Scrubs and Heels Summit
21. S977 Health Disparities in the Care of Patients With Inflammatory Bowel Disease: A Focus on Preventive Care & the Patient Perspective
22. S852 Long-Term Clinical and Endoscopic Outcomes in True North Week 52 Clinical Remitters Over 3 Years of Treatment With Ozanimod: An Interim Analysis of the True North Open-Label Extension Study
23. Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension
24. A women-focused matrix mentorship programme in gastroenterology
25. A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and Persistence With Inflammatory Bowel Disease Therapy (ASSIST Study): Protocol for a Randomized Controlled Trial
26. S76 An Interim Analysis of 2 Years of Continuous Ozanimod Treatment From the True North Open-Label Extension Study
27. S1 Sarcopenia Is Associated With Social Determinants of Health in Patients With Inflammatory Bowel Disease
28. The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium
29. S799 Health-Related Quality of Life with Guselkumab Induction and Maintenance Therapy as Measured by PROMIS-29: Results Through Week 48 of Phase 2 GALAXI 1 Study
30. S810 Efficacy Outcomes by Symptom-Based Response Status After Induction: Week-48 Results from the GALAXI 1 Trial of Guselkumab in Crohn’s Disease
31. S731 Ozanimod Is an Effective Oral Treatment for Patients With Ulcerative Colitis Regardless of Baseline Endoscopic Disease Distribution: A Post Hoc Analysis of the Phase 3 True North Study
32. S757 Efficacy and Safety of 2 Years of Continuous Ozanimod Treatment: Interim Analysis of the True North Open-Label Extension Study
33. S2764 Racial and Ethnic Differences in Diagnosed Prevalence, Specialist Visits, and Treatment Utilization of Inflammatory Bowel Disease: Retrospective Analysis of U.S. Claims Data
34. S1493 Impostor Phenomenon and Microaggression Education and Self-Assessment in Female Healthcare Professionals in the Field of Gastroenterology
35. S938 Gender-Based Differences in Sarcopenia Screening With the SARC-F Questionnaire in Inflammatory Bowel Disease
36. S876 Efficacy of Deucravacitinib, an Oral, Selective, TYK2 Inhibitor, in Patients With Moderately to Severely Active Ulcerative Colitis and Prior Exposure to Biologic Therapy: Subanalysis From the Phase 2 LATTICE-UC Study
37. Gender barriers are worsening women's access to health care in Afghanistan
38. A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence with Inflammatory Bowel DiSease Therapy—ASSIST Study: A Randomized Controlled Trial (Preprint)
39. Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting
40. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
41. 888: EFFICACY AND SAFETY OF GUSELKUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 48 ANALYSES FROM THE PHASE 2 GALAXI 1 STUDY
42. Su1505: IMPACT OF CONCOMITANT PROTON PUMP INHIBITOR AND ADVANCED THERAPY USE ON HEALTH OUTCOMES OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE
43. Su1510: IDENTIFYING THE MOST EFFECTIVE TREATMENT ALGORITHM FOR THERAPIES TO TREAT MODERATE TO SEVERE ULCERATIVE COLITIS
44. Tu1458: LONG-TERM USE OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
45. Tu1472: RAPIDITY OF OZANIMOD-INDUCED SYMPTOMATIC RESPONSE AND REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE INDUCTION PERIOD OF TRUE NORTH
46. Tu1450: EXTENDED THERAPY WITH OZANIMOD FOR DELAYED RESPONDERS TO OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
47. 969: RECAPTURE OF RESPONSE WITH OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO WITHDREW THERAPY: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
48. EFFICACY AND SAFETY OF GUSELKUMAB THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS OF THE GALAXI 2 & 3 PHASE 3 STUDIES
49. Su1792 EFFICACY OUTCOMES OF PLACEBO MAINTENANCE TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO RESPONDED TO PLACEBO INDUCTION THERAPY: RESULTS FROM THE PHASE 3 COMMAND STUDY
50. Su1797 ETRASIMOD SHOWS LOW RISK OF ADVERSE EVENTS FOLLOWING CONCOMITANT USE WITH OPIOIDS OR ANTIDEPRESSANTS IN PATIENTS WITH ULCERATIVE COLITIS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.